NXTC Stock Forecast: NextCure, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for NextCure, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores NextCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NXTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NXTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $25 |
| 7 Nov 2025 | Ladenburg Thalmann | Upgrade | Buy | — |
| 15 July 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Aug 2024 | Needham | Reiterates | Buy | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | Needham | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2024 | Needham | Maintains | Buy | — |
| 14 Dec 2023 | Needham | Maintains | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 4 Aug 2023 | Needham | Reiterates | Buy | — |
| 5 May 2023 | Needham | Reiterates | Buy | — |
| 3 Mar 2023 | Needham | Reiterates | Buy | — |
| 4 Nov 2022 | Ladenburg Thalmann | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NXTC.
This page is one stock. Monday covers all of them.
NXTC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NXTC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, NextCure, Inc. returned −30.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NXTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 5.6×
- EV / EBITDA
- —
Cheaper than 15% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −281.1%
- Return on assets
- −98.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NextCure, Inc. has a market value of $31.0M and an enterprise value of $22.3M.
Free cash flow in the twelve months to 30 June 2026: −$37.0M.
NextCure, Inc. employs 40 people.
Data provided by Twelve Data
NXTC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NXTC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own NextCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NXTC
What is the NXTC stock price forecast for 2026-2027?
The median 12-month analyst price target for NextCure, Inc. is $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NXTC stock a buy right now?
Of the 1 analyst covering NextCure, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NextCure, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NXTC?
As at 21 Nov 2026, NextCure, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will NXTC stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $20, and Ticker Nerd's factor model ranks NextCure, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NXTC stock forecast for 2030?
No analyst covering NextCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
How has NXTC stock performed over the past year?
NextCure, Inc. returned -30.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NextCure, Inc. do?
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company’s work centers on identifying biological pathways, biomarkers, and immune-cell interactions within the tumor microenvironment to create therapies for patients whose cancers do not respond well to current treatments.
About NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company’s work centers on identifying biological pathways, biomarkers, and immune-cell interactions within the tumor microenvironment to create therapies for patients whose cancers do not respond well to current treatments. Its current programs emphasize targeted approaches such as antibody-drug conjugates and other differentiated mechanisms of action designed to address difficult-to-treat tumors. NextCure also uses its FIND-IO discovery platform to help identify novel immune targets and support pipeline development. Headquartered in Beltsville, Maryland, NextCure plays a specialized role in the oncology and immunology markets by advancing experimental therapies intended to improve treatment options for patients with limited alternatives.
CEO Mr. Michael S. Richman MSBA · 40 employees · United States · https://www.nextcure.com